R. Griffiths

发表

Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice.

A. Rudensky, J. Stock, J. Mcneish, 1999, Immunity.

Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram

E. Pettipher, E. Salter, R. Griffiths, 1996, British journal of pharmacology.

Post-capillary venules in the “milky spots” of the greater omentum are the major site of plasma protein and leukocyte extravasation in rodent models of peritonitis

A. Milici, J. Hakkinen, R. Griffiths, 1995, Inflammation Research.

Induction of hepatic microsomal drug-metabolizing enzymes by inhibitors of 5-lipoxygenase (5-LO): studies in rats and 5-LO knockout mice.

J. Mcneish, D. Amacher, W. Beierschmitt, 2001, Toxicological sciences : an official journal of the Society of Toxicology.

Characterisation and pharmacological sensitivity of antigen arthritis induced by methylated bovine serum albumin in the rat

R. Griffiths, 2005, Agents and Actions.

(+)-1-(3S,4R)-[3-(4-phenylbenzyl)-4-hydroxychroman-7-yl]cyclopentane carboxylic acid, a highly potent, selective leukotriene B4 antagonist with oral activity in the murine collagen-induced arthritis model.

A. Milici, E. Pettipher, L. Melvin, 1994, Journal of medicinal chemistry.

Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice.

B. Koller, J. Snouwaert, R. Byrum, 1999, Journal of immunology.

The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543.

M. Smith, A. Milici, E. Pettipher, 1998, The Journal of pharmacology and experimental therapeutics.

Collagen-induced Arthritis Is Reduced in 5-Lipoxygenase-activating Protein-deficient Mice

B. Koller, J. Stock, J. Mcneish, 1997, The Journal of experimental medicine.

FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor

W. T. Simpson, R. Griffiths, J. Mann, 1990, Agents and Actions.

Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors.

C. Gabel, D. Perregaux, J. Eggler, 2001, The Journal of pharmacology and experimental therapeutics.

Interleukin‐1β posttranslational processing—exploration of P2X7 receptor involvement

C. Gabel, B. Koller, D. Perregaux, 2001 .

Characterisation of passively transferred antigen arthritis induced by methylated bovine serum albumin in the rat: Effect of FK 506 on arthritis development

R. Griffiths, M. E. Mather, S. Li, 1992, Agents and Actions.

The effect of FK506 and cyclosporin A on antigen‐induced arthritis

R. Griffiths, A. Blackham, 1991, Clinical and experimental immunology.

Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis.

M. Smith, A. Milici, E. Pettipher, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models

P. Pazoles, T. Carty, P. F. Moore, 1997, Inflammation Research.

Collagen-induced Arthritis Is Reduced in 5-Lipoxygenase-activating Protein-deﬁcient Mice

B. Koller, J. Mcneish, R. Byrum, 1997 .

Pharmacological modification of 12-O-tetradecanoylphorbol-13-acetate induced inflammation and epidermal cell proliferation in mouse skin

B. E. Wood, R. Griffiths, A. Blackham, 1988, Agents and Actions.

Interaction of prostaglandins and clonidine in the rat vas deferens

P. Moore, R. Griffiths, P. K. Moore, 1982, The Journal of pharmacy and pharmacology.

A comparison of the anti-inflammatory activity of selective 5-lipoxygenase inhibitors with dexamethasone and colchicine in a model of zymosan induced inflammation in the rat knee joint and peritoneal cavity

B. E. Wood, R. Griffiths, A. Blackham, 1991, Agents and Actions.

GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF.

W. Brissette, J. Umland, R. Griffiths, 1995, Cytokine.

The Phosphodiesterase Type 4 (PDE4) Inhibitor CP-80,633 Elevates Plasma Cyclic AMP Levels and Decreases Tumor Necrosis Factor-α (TNFα) Production in Mice: Effect of Adrenalectomy

E. Pettipher, H. Showell, John B. Cheng, 1997 .

28 – The Use of Animals in the Search for Anti-inflammatory Drugs

R. Griffiths, 1995 .

Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13.

D. Danley, J. Pandit, E. Laird, 2007, Bioorganic & Medicinal Chemistry Letters.

Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.

I. Otterness, R. Robinson, J. Liras, 2004, Bioorganic & medicinal chemistry letters.

A modified mouse air pouch model for evaluating the effects of compounds on granuloma induced cartilage degradation

R. Griffiths, A. Steward, T. J. Rising, 1988, British journal of pharmacology.

Enzymatic inactivation of 6-keto-prostaglandin E1 in vitro: comparison with prostaglandin E1.

P. Moore, J. Hoult, R. Griffiths, 1984, Biochemical pharmacology.

Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea‐pig and human platelets

R. Griffiths, P. K. Moore, 1983, British journal of pharmacology.

The effect of some flavone drugs on the conversion of prostacyclin to 6-oxoprostaglandin E1.

P. Moore, R. Griffiths, F. Lofts, 1983, Biochemical pharmacology.

Formation of 6‐keto prostaglandin E1 in mammalian kidneys

R. Griffiths, P. K. Moore, P.K. Moore, 1983, British journal of pharmacology.

Role of the 5-Lipoxygenase–activating Protein (FLAP) in Murine Acute Inflammatory Responses

B. Koller, R. Byrum, J. Goulet, 1997, The Journal of experimental medicine.

Altered Cytokine Production in Mice Lacking P2X7Receptors*

Beverly H. Koller, C. Gabel, B. Koller, 2001, The Journal of Biological Chemistry.

The effect of 6‐oxo‐prostaglandin E1 on human platelet aggregation in whole blood in‐vitro

R. Griffiths, F. Lofts, P. K. Moore, 1985, The Journal of pharmacy and pharmacology.

The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.

E. Pettipher, J. Cheng, H. Showell, 1997, Journal of Pharmacology and Experimental Therapeutics.

Pre-synaptic and post-synaptic effects of xylazine and naphazoline on the bisected rat vas deferens.

P. Moore, R. Griffiths, 1982, Archives internationales de pharmacodynamie et de therapie.

ATP induces the release of IL-1 from LPS-primed cells in vivo.

I. Otterness, R. Griffiths, J. Downs, 1995, Journal of immunology.

Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.

D. Danley, J. Pandit, E. Laird, 2005, Bioorganic & medicinal chemistry letters.

Identification of 6‐oxo‐prostaglandin E1 as a naturally occurring prostanoid generated by rat lung

J. Hoult, R. Griffiths, P. K. Moore, 1986, British journal of pharmacology.

Catabolism of 6 keto PGE1: biological activation by the rat kidney in vitro.

P. Moore, R. Griffiths, Z. Gaffen, 1983, European journal of pharmacology.

Age-dependent changes in the synthesis and catabolism of 6 oxo PGE1 and other prostanoids by the rat kidney in vitro.

P. Moore, J. Hoult, R. Griffiths, 1985, Biochemical Pharmacology.

Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.

I. Otterness, R. Robinson, J. Liras, 2004, Bioorganic & medicinal chemistry letters.

Analgesic activity of 2-amino-4-methylpyridine, a novel NO synthase inhibitor

E. Pettipher, R. Griffiths, T. A. Hibbs, 1997, Inflammation Research.